Knight Therapeutics Inc.
TSX: GUD.TO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Samira Sakhia
- Employees
- 745
- Headquarters
- Montreal, Canada
- IPO year
- 2014
- Market cap
- CA$852.1M
- Website
- https://www.gud-knight.com
Loading GUD…
Loading profile data…Frequently asked questions about GUD
What does Knight Therapeutics Inc. (GUD.TO) do?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for r...
Where does GUD.TO trade?
Knight Therapeutics Inc. (GUD.TO) trades on the Toronto Stock Exchange.
What sector is GUD.TO in?
Knight Therapeutics Inc. (GUD.TO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Knight Therapeutics Inc.?
Samira Sakhia is the chief executive officer of Knight Therapeutics Inc. (GUD.TO).
Where is Knight Therapeutics Inc. headquartered?
Knight Therapeutics Inc. is headquartered in Canada.
Does GUD.TO pay a dividend?
Knight Therapeutics Inc. (GUD.TO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GUD.TO go public?
Knight Therapeutics Inc. (GUD.TO) completed its initial public offering in 2014.